Pharmaceutical Commerce Magazine

Pharmaceutical Commerce Magazine Business Strategies for Bio/Pharma Success

Are your thermal tests ready for real-world conditions?Join our webinar to explore best practices, overlooked variables,...
03/11/2026

Are your thermal tests ready for real-world conditions?

Join our webinar to explore best practices, overlooked variables, and key questions cold chain professionals should be asking to qualify solutions with confidence.

Register now: https://hubs.li/Q045JGNK0

Redefining How Medicines Reach Patients with Next-Gen Supply ChainsJay McHarg, CEO of AeroSafe Global, reacts to the nex...
03/05/2026

Redefining How Medicines Reach Patients with Next-Gen Supply Chains

Jay McHarg, CEO of AeroSafe Global, reacts to the next generation of pharma delivery using innovations such as reusable packaging, integrated delivery systems, and real-time delivery intelligence.

Watch Now: https://hubs.li/Q03ZRSfk0

Thermal testing plays a critical role in protecting temperature-sensitive shipments but not all testing approaches accou...
03/03/2026

Thermal testing plays a critical role in protecting temperature-sensitive shipments but not all testing approaches account for the variables that matter most.

In this upcoming webinar, we’ll cover best practices in thermal testing, explore often-overlooked testing variables, and share the key questions cold chain professionals should be asking to ensure reliable, real-world results.

Register now to learn how to qualify solutions with confidence: https://hubs.li/Q045cZKx0

Cutting Product Loss and Carbon Emissions in Pharma Supply ChainsJay McHarg, CEO of AeroSafe Global, explains how a Targ...
02/19/2026

Cutting Product Loss and Carbon Emissions in Pharma Supply Chains

Jay McHarg, CEO of AeroSafe Global, explains how a Targeted Risk Improvement Program improves resilience, reduces costs, and strengthens sustainability across the supply chain.

Watch Now: https://hubs.li/Q03ZRRqs0

Predicting Risk Before It HappensJay McHarg, CEO of AeroSafe Global, discusses the significance of rethinking the “last ...
02/05/2026

Predicting Risk Before It Happens

Jay McHarg, CEO of AeroSafe Global, discusses the significance of rethinking the “last mile” as the first moment of patient care—using real-time Active Delivery Management—for proactive and improved pharmaceutical logistics.

Watch Now: https://hubs.li/Q03ZRRpR0

The Future of Pharma LogisticsHear how “delivery intelligence” is transforming the last mile of pharmaceutical logistics...
01/22/2026

The Future of Pharma Logistics

Hear how “delivery intelligence” is transforming the last mile of pharmaceutical logistics from Jay McHarg, CEO of AeroSafe Global.

Watch Now: https://hubs.li/Q03ZR9650

12/23/2025

Wishing you a wonderful holiday season from the team at Pharmaceutical Commerce! ❄️ 🎁

Global pricing shifts, launch sequencing, and models—our webinar covered it all. Watch Part 1 on demand now. https:/...
09/17/2025

Global pricing shifts, launch sequencing, and models—our webinar covered it all. Watch Part 1 on demand now. https://hubs.li/Q03JwRh-0

Part 2 will air in early October. You can engage in the live discussion or view it later on demand.

Register here: https://hubs.li/Q03JwRkR0

could reshape global pricing dynamics and disrupt distribution channels across pharma. Pharmaceutical Commerce® invite...
08/29/2025

could reshape global pricing dynamics and disrupt distribution channels across pharma. Pharmaceutical Commerce® invites you to a 3-part roundtable exploring how MFN may affect , and international pricing.

Date: September 10, 2025
Time: 7:00 p.m. EDT
Location: Live Webinar

Join the lively discussion: https://hubs.ly/Q03G4mDJ0

09/12/2024

The parties’ want to provide customers with a “one-stop-shop,” with the hopes that their services will be easier to navigate.

09/12/2024

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients ...
09/11/2024

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.

Address

2 Clarke Drive #100
Cranbury, NJ
08512

Telephone

+16097167777

Website

Alerts

Be the first to know and let us send you an email when Pharmaceutical Commerce Magazine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Pharmaceutical Commerce Magazine:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category